From Polymorph Screening to Dissolution Testing : Solid Phase Analysis during Pharmaceutical Development and Manufacturing by Aaltonen, Jaakko
Division of Pharmaceutical Technology 
Faculty of Pharmacy 
University of Helsinki 
 
 
 
 
 
 
 
 
From Polymorph Screening  
to Dissolution Testing 
 
 
Solid Phase Analysis during Pharmaceutical  
Development and Manufacturing 
 
by 
Jaakko Aaltonen 
 
 
 
 
 
 
ACADEMIC DISSERTATION 
 
To be presented, with the permission of the Faculty of Pharmacy of the University of 
Helsinki, for public criticism in auditorium 2 at Viikki Infocentre (Viikinkaari 11), on 
March 30th 2007, at 12 noon. 
 
 
 
 
Helsinki 2007 
Supervisors:  Professor Jukka Rantanen1, 2
1Department of Pharmaceutics and Analytical Chemistry 
  Faculty of Pharmaceutical Sciences 
University of Copenhagen 
Denmark 
 
2Drug Discovery and Development Technology Center 
Faculty of Pharmacy 
  University of Helsinki 
  Finland 
 
  Professor Jouko Yliruusi 
  Division of Pharmaceutical Technology 
  Faculty of Pharmacy 
  University of Helsinki 
  Finland 
 
 
Reviewers:  Associate Professor Lars Hovgaard 
  Department of Pharmaceutics and Analytical Chemistry 
Faculty of Pharmaceutical Sciences   
University of Copenhagen 
Denmark 
 
Professor Jari Yli-Kauhaluoma 
  Division of Pharmaceutical Chemistry 
  Faculty of Pharmacy 
University of Helsinki 
Finland 
 
 
Opponent:  Professor Thomas Rades 
  School of Pharmacy 
University of Otago 
  Dunedin 
  New Zealand 
 
 
© Jaakko Aaltonen 
ISBN 978-952-10-3806-8 (paperback) 
ISBN 978-952-10-3807-5 (PDF, http://ethesis.helsinki.fi) 
ISSN 1795-7079 
 
Helsinki University Printing House 
Helsinki, Finland, 2007 
  
Abstract 
Aaltonen, J.J., 2007. From Polymorph Screening to Dissolution Testing – Solid Phase 
Analysis during Pharmaceutical Development and Manufacturing. 
 
Dissertationes bioscientiarum molecularium Universitatis Helsingiensis in Viikki, 
9/2007, 41 pp.  
 
ISBN 978-952-10-3806-8 (paperback), ISBN 978-952-10-3807-5 (pdf), ISSN 1795-7079 
 
Solid materials can exist in different physical structures without a change in chemical 
composition. This phenomenon, known as polymorphism, has several implications on 
pharmaceutical development and manufacturing. Various solid forms of a drug can 
possess different physical and chemical properties, which may affect processing 
characteristics and stability, as well as the performance of a drug in the human body. 
Therefore, knowledge and control of the solid forms is fundamental to maintain 
safety and high quality of pharmaceuticals. During manufacture, harsh conditions 
can give rise to unexpected solid phase transformations and therefore change the 
behavior of the drug. Traditionally, pharmaceutical production has relied on time-
consuming off-line analysis of production batches and finished products. This has led 
to poor understanding of processes and drug products. Therefore, new powerful 
methods that enable real time monitoring of pharmaceuticals during manufacturing 
processes are greatly needed.  
The aim of this thesis was to apply spectroscopic techniques to solid phase 
analysis within different stages of drug development and manufacturing, and thus, 
provide a molecular level insight into the behavior of active pharmaceutical 
ingredients (APIs) during processing. Applications to polymorph screening and 
different unit operations were developed and studied. A new approach to 
dissolution testing, which involves simultaneous measurement of drug concentration 
in the dissolution medium and in-situ solid phase analysis of the dissolving sample, 
was introduced and studied.  
Solid phase analysis was successfully performed during different stages, 
enabling a molecular level insight into the occurring phenomena. Near-infrared 
(NIR) spectroscopy was utilized in screening of polymorphs and processing-induced 
transformations (PITs). Polymorph screening was also studied with NIR and Raman 
spectroscopy in tandem. Quantitative solid phase analysis during fluidized bed 
drying was performed with in-line NIR and Raman spectroscopy and partial least 
squares (PLS) regression, and different dehydration mechanisms were studied using 
in-situ spectroscopy and partial least squares discriminant analysis (PLS-DA). In situ 
solid phase analysis with Raman spectroscopy during dissolution testing enabled 
analysis of dissolution as a whole, and provided a scientific explanation for changes 
in the dissolution rate. It was concluded that the methods applied and studied 
provide better process understanding and knowledge of the drug products, and 
therefore, a way to achieve better quality.  
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1. Introduction 
Research and development of a new drug is an expensive and lengthy process. On 
average it takes 10-15 years for a drug to progress from laboratory to pharmacy, and 
the success rate is low: only five per 5000 compounds screened enter clinical trials 
and one of those five eventually enters the market (PhRMA, 2005). Research and 
development costs of a drug have been estimated to exceed US $800 million  (DiMasi 
et al., 2003). Considering the size of the pharmaceutical industry – in 2005 the global 
sales of pharmaceuticals was worth US $602 billion (IMS Health, 2006) – and the fact 
that medication safety is of extreme importance, it is somewhat surprising that 
quality control and assurance still relies quite heavily on off-line analysis of 
production batches and finished products (Abboud and Hensley, 2003). Such analyses 
are time-consuming and provide very little information on product behavior during 
processing. If a production batch does not meet specifications it has to be discarded. 
In such a case, information lacking off-line analyses provide little help for 
troubleshooting. Therefore, new and efficient methods of process analysis are truly 
needed within the pharmaceutical industry. 
Decisions determining the directions of further development of the drug 
product are made at an early stage of drug development. During preformulation 
stage physicochemical properties of candidate drugs and the conditions under which 
the candidate drug should be formulated are investigated. Key issues include 
investigation of polymorphism, the ability of a compound to exist in more than one 
crystalline form, and careful selection of the solid form for further development. The 
term polymorphism is often used broadly to refer to, in addition to true crystalline 
polymorphs, also to other solid forms (hydrates/solvates and amorphous form) 
(Hilfiker, 2006). The selection of the solid form of the active pharmaceutical 
ingredient (API) is made after polymorph screening, during which several solid forms 
of the candidate drug are generated and analyzed. Even though it is called 
polymorph screening, it is understood that other solid forms cannot be neglected, 
since they may possess properties which make them the most suitable for 
development. 
During various unit operations used in pharmaceutical production the 
materials are subject to mechanical and/or thermal stress, high moisture content and 
contact with solvents, which set the scene for solid phase transformations from one 
solid form to another. Such processing-induced transformations (PITs) are well 
known but difficult to predict or control (Morris et al., 2001). On these accounts it 
should be obvious that monitoring of the solid forms should not be stopped once 
the desired solid form is chosen after polymorph screening. In order to fully 
understand the behavior of a given drug the solid state of the API should be 
continuously monitored and analyzed as long as it exists as a solid – from 
crystallization, via various process steps and shelf-life, until the drug is dissolved after 
administration (in vitro dissolution testing) (figure 1).  
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Figure 1. A simplified graph of various steps an API may be subjected to during 
pharmaceutical development and manufacturing. To fully understand the 
behavior of the API and the final dosage form, solid phase analysis should 
be carried out during every step.   
Spectroscopic techniques enable continuous and real time solid phase analysis during 
processing. Despite recent advances in manufacturing and analytical technologies 
the industry has been reluctant to make use of novel methods that would enable 
better understanding of products and processes, and hence better quality. This has 
been due to a strict regulatory environment unfavorable to introduction of 
innovative systems (Abboud and Hensley, 2003), and also the high cost of 
introducing new methods, even though in long term it would probably be 
beneficial. Lately, however, regulatory authorities have taken the initiatives and 
published guidelines to encourage pharmaceutical manufacturers to utilize 
advanced methods to ensure high drug product quality (FDA, 2004a; ICH, 2005a; ICH, 
2005b). The process analytical technology (PAT) guideline emphasizes the 
importance of real time monitoring of manufacturing processes (FDA, 2004b). In 
addition to above-mentioned economical and regulatory issues, there is still one 
more obstacle on the way to successful implementation of these advanced 
techniques: the cultural change needed in the laboratories. This may, in fact, be the 
most important one. 
In this thesis, approaches to solid phase analysis using spectroscopic methods 
are taken. Case studies of polymorph screening, pharmaceutical unit operations, as 
well as dissolution testing are provided. The literature review focuses on the solid 
phase, importance of solid-state properties, and generation of different solid forms. 
Basic principles of the measurement techniques are well established, and therefore 
left out. 
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2. Theory and literature review 
2.1 Solid phase 
A phase is defined as a homogeneous, physically distinct and mechanically separable 
portion of a system. Examples are gases, liquids and solids. Solid phase can be 
crystalline or amorphous. In the crystalline state (polymorphs) the constituent 
molecules are regularly arranged into a fixed and rigid repeating array known as a 
lattice, whereas the amorphous state lacks a definite long-range order (Byrn et al., 
1999b; Grant, 1999). The smallest three-dimensional volume element from which 
crystals can be built is the unit cell. When a volatile solvent molecule occupies 
regular positions in the crystal lattice, the solid is called a solvate, and if the volatile 
solvent molecule is water, the term hydrate is used.  Figure 2 is a schematic 
representation of the solid forms mentioned.  
 
Figure 2. Arrangement of molecules in different types of solid material. 
2.1.1 Polymorphs 
Polymorphism in molecular crystals is defined as the ability of a compound to 
crystallize in more than one crystalline phase (Bernstein, 2002b). In the strictest sense 
polymorphism refers only to crystalline solid forms that accompany molecules of only 
one chemical species in the crystal lattice. According to McCrone, every compound 
has different polymorphic forms, and the number of forms known for a given 
compound is proportional to the time and money spent in research on that 
compound (McCrone, 1965). A good example of this is ROY (Chen et al., 2005) a 
compound that, at present, has seven reported crystal structures in Cambridge 
Structural Database (CSD) (Allen, 2002). 
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There are two ways in which different crystal lattices can be formed: packing 
polymorphism and conformational polymorphism. Packing polymorphism denotes 
crystal forms of a compound where rigid molecules with uniform conformation are 
packed in different arrangements, whereas conformational polymorphism refers to 
crystal forms where flexible molecules with different conformations are packed in 
different arrangements (Grant, 1999). Known examples of packing and 
conformational polymorphism are paracetamol (Boldyreva et al., 2002) and l-
glutamic acid, respectively (Davey et al., 1997). 
The Gibbs free energy of a polymorph is defined as 
G = H – TS    (1) 
where G is the Gibbs free energy, H is the enthalpy and TS is the entropy term (fig. 
3). Thermodynamically, only one polymorph is stable at a given temperature and a 
constant pressure. The stable form is that with the lowest Gibbs free energy in the 
given conditions and is the least soluble form. The order of polymorph stability is 
defined by the difference in Gibbs free energies 
∆G = ∆H – T∆S    (2) 
In an enantiotropic polymorphic system the stable polymorph is different above and 
below a transition temperature. At the transition temperature, ∆G = 0 (fig. 4a). In a 
monotropic system one polymorph is always more stable than the other below the 
melting point of either form (fig. 4b). In addition to thermodynamics the existence 
of different polymorphs is controlled by kinetics. Therefore, other 
thermodynamically unstable forms with a higher Gibbs free energy can exist in the 
given conditions, and are known as metastable forms. 
 
Figure 3. Energy-temperature plot of a crystalline solid under constant pressure. 
Modified from Lohani and Grant (2006). 
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Figure 4. Energy–temperature diagram of (a) an enantiotropic system and (b) a 
monotropic system where G is the Gibbs free energy; T is the 
temperature; A, B and Liq refer to polymorph A, polymorph B, and the 
liquid phase, respectively; Tt is the transition point between A and B, and 
TmA and TmB are the melting points of A and B, respectively. Tt of the 
monotropic system is virtual since it is above TmA and TmB. Modified from 
Burger and Ramberger (1979). 
2.1.2 Hydrates  
Hydrates are the most important subclass of solvates. This is due to water being the 
most common solvent used in processing, and also because of the omnipresence of 
water in the environment. In addition, the small size of the water molecule and its 
multidirectional hydrogen bonding capability facilitate incorporation into the crystal 
lattice and stabilization of the crystal structure (Byrn et al., 1999a; Gillon et al., 
2003). It has been estimated that every third drug molecule is capable of forming a 
hydrate (Stahl, 1980). Hydrates and solvates also exhibit polymorphism.  
Hydrates can be classified into three categories: 1) isolated site hydrates, 2) 
channel hydrates and 3) ion associated hydrates (Morris, 1999). In the crystal 
structure of an isolated site hydrate the water molecules are isolated from direct 
contact with other water molecules by the API molecules, whereas in channel 
hydrates the water molecules are located next to each other along one direction in 
the lattice. Hydrates can contain stoichiometric or nonstoichiometric amounts of 
water molecules per API molecule. An expanded channel hydrate can take up water 
into the channels when exposed to high humidity and release water when exposed 
to relatively low humidity (Datta and Grant, 2004). The crystal lattice of such 
hydrates can expand or contract as hydrate formation or dehydration proceeds, 
changing the dimensions of the unit cell. In ion associated hydrates, the water 
molecules are coordinated by ions incorporated in the crystal lattice. 
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The stability of hydrates is governed by the water activity of the environment, and 
the intermolecular bonding and arrangement of molecules in the lattice. Therefore, 
the critical water activity that determines whether the stable form is the anhydrate 
or the hydrate (or lower hydrate / higher hydrate) is drug-specific. Hydrates are more 
stable than their anhydrous counterparts at conditions below dehydration 
temperature and above critical water activity, such as high humidity or saturated 
aqueous solution. Isolated site hydrates usually dehydrate at relatively high 
temperatures. The dehydration process of such hydrates is destructive for the crystal 
structure since it requires rearrangement of the molecules in the unit cell in order to 
allow water molecules to escape the lattice. An example is dehydration process of 
nitrofurantoin monohydrate, during which a partially amorphous intermediate form 
is detected (Kishi et al., 2002; Karjalainen et al., 2005). Channel hydrates usually 
dehydrate at lower temperatures than isolated site hydrates. Theophylline 
monohydrate is an example of a channel hydrate. It dehydrates (via a metastable 
phase) at lower temperatures than nitrofurantoin monohydrate, and even though 
an intermediate metastable form is detected, the dehydration process does not 
involve a collapse of the crystal structure (Phadnis and Suryanarayanan, 1997). In ion 
associated hydrates the bonding between the metal ion and the water molecule can 
be strong, which results in very high dehydration temperatures (Morris, 1999).   
2.1.3 Amorphous solids 
Solid materials can be intrinsically amorphous or intentionally made amorphous by 
physical manipulation (Hancock and Zografi, 1997). Amorphous forms are 
metastable, higher-energy forms than their crystalline counterparts and tend to 
release their energy through crystallization. They are hygroscopic and absorb 
moisture which acts as a plasticizer and promotes molecular mobility, which leads to 
crystallization. Thus humidity and aqueous environments further reduce the stability 
of amorphous solids. Even though amorphous forms lack definite long-range order, 
they typically exhibit short-range order over a few molecular dimensions. Organic 
compounds have not been shown to exhibit polyamorphism (characterized by a 
transition between two amorphous states), which has been reported for inorganic 
compounds (Petit and Coquerel, 2006).  
2.2 Importance of solid-state properties 
Different solid forms have different physicochemical properties that may 
significantly affect the performance of an API (Haleblian and McCrone, 1969; 
Threlfall, 1995). Examples of these properties are listed in table 1. 
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Table 1. Physical properties that differ among various solid forms. Modified 
from Grant (1999). 
Packing properties Unit cell volume (crystalline forms only), density, refractive 
index, hygroscopicity 
Thermodynamic properties Melting point, enthalpy, entropy, free energy, solubility 
Spectroscopic properties Electronic transitions (UV-vis spectra), vibrational transitions 
(IR and Raman spectra), rotational transitions (far-IR or 
microwave spectra), nuclear spin transitions (NMR spectra) 
Kinetic properties Dissolution rate, rates of solid state reactions, stability 
Surface properties Surface free energy, interfacial tensions, crystal habit 
Mechanical properties Hardness, tensile strength, compactibility, tableting, 
flowability 
 
The differences in the mechanical properties can affect processing behavior, which is 
the case with paracetamol polymorphs (Di Martino et al., 1996), where form II is 
suitable for direct tablet compression, but form I needs to be mixed with binding 
agents prior to compression (Nichols and Frampton, 1998). Polymorphs I and II of 
sulfamerazine have also been reported to show different tableting properties (Sun 
and Grant, 2001), as well as different forms of theophylline (Suihko et al., 2001).  
The performance of the drug in the human body can depend on the solid 
form, if solubility and dissolution rate are dependent on the solid state of the API. 
Well-known examples are carbamazepine (Kahela et al., 1983; Meyer et al., 1992) 
and ritonavir (Chemburkar et al., 2000).  
Physical stability may depend on the solid form. This is an important issue 
since solid dosage forms may be stored for prolonged periods and naturally, the 
solid state of the API must not change during its shelf-life. The poor stability of 
amorphous forms is one of the biggest hurdles to developing formulations with 
amorphous APIs (Kaushal et al., 2004). In addition to physical stability, chemical 
stability can also be different because chemical reactivity can vary between different 
solid forms (Byrn et al., 2001). For example, chemical stability differences between 
polymorphs of prednisolone tert-butylacetate (Byrn et al., 1988), and between 
crystalline and amorphous form of quinapril hydrochloride (Guo et al., 2000) have 
been published.  
Different solid forms of an API also have major economic implications, since 
they can be patented. Different interpretations of polymorph patents have caused 
controversy between drug manufacturers. The best-known case is polymorphism of 
ranitidine hydrochloride, which has given rise to several patent trials (Bernstein, 
2002a). Unexpected solid phase transformations, sudden appearance or 
disappearance of polymorphs, and sometimes, differences in determining 
polymorphic purity, can make patent interpretation everything but simple. 
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2.3 Generation of different solid forms  
2.3.1 Polymorph screening 
The purpose of polymorph screening is to, first, find the different solid forms the API 
may exhibit, and second, choose the form most suitable for further development 
(Hilfiker et al., 2006). Even though the stable form would normally be the safest 
choice, there are cases in which other forms are more suitable (Singhal and Curatolo, 
2004). In this situation, a metastable form is usually selected for an enhanced 
solubility or dissolution rate.  
Polymorph screening can be approached either experimentally or by 
computational methods (Price, 2004). Even though computational methods have 
advanced markedly during the last years, experimental work is still needed since the 
difference in lattice energy between polymorphs can be small making polymorph 
prediction very challenging. Furthermore, crystallization phenomena, especially 
nucleation, are not yet fully understood (Davey, 2004). A combination of crystal 
structure prediction and targeted experimental crystallizations has been published 
(Cross et al., 2003). However, since properties are compound-specific, there are no 
common guidelines how to perform experimental polymorph screening. Some 
general suggestions and guidelines for systematic screening have been published 
(Byrn et al., 1995; ICH, 1999; Yu et al., 2003).  
There are several approaches to produce different solid forms of an API (table 
2). During polymorph screening different methods with varying parameters should 
be trialed. Crystallization from solution is the most widely used method (Mullin, 
2001), with the solvent the most influential variable. Various solvents with different 
properties are used in polymorph screening experiments, but unfortunately 
publications on rational solvent selection are rare. Principal component analysis 
(Carlson et al., 1985) and cluster analysis (Gu et al., 2004) basing on molecular 
descriptors have been used for solvent classification. 
High-throughput polymorph screening 
High-throughput methods for polymorph screening have been developed to 
perform polymorph screening rapidly with a small amount of drug. High-throughput 
polymorph screening is usually performed with automated crystallization stations 
that include robotic systems for liquid handling and solid phase analysis (Storey et 
al., 2004). Possible bottlenecks during high-throughput polymorph screening are the 
experimental crystallizations, solid form analysis, and data analysis. High-throughput 
crystallizations can be performed on well-plate systems, or at an even smaller scale 
such as on a chip (Lee et al., 2006), or self-assembled monolayers (Lee et al., 2005). 
Crystallizations on small scale certainly bring saving in time and material, but scale-
up problems are probable, since small-scale crystallizations cannot always be 
reproduced at the production scale. The gold standard in solid phase analysis is X-ray 
powder diffraction (XRPD), but Raman spectroscopy is receiving more attention 
because much smaller scale solid phase analysis is feasible (Peterson et al., 2002; 
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Anquetil et al., 2003; Remenar et al., 2003). Regardless of the method of analysis a 
large amount of data is produced, and therefore different multivariate methods for 
data analysis and pattern identification have been suggested (Peterson et al., 2002; 
Remenar et al., 2003; Barr et al., 2004a; Barr et al., 2004c; Barr et al., 2004b; Gilmore 
et al., 2004; Ivanisevic et al., 2005). 
Table 2. Methods to prepare various solid forms (Guillory, 1999; Mullin, 2001; 
Yu, 2001; Hilfiker et al., 2006). Crystalline forms can be prepared by all
listed methods and those marked with (A) can also be used to prepare 
amorphous forms. 
 
Method Degrees of freedom 
Crystallization by cooling a 
solution 
Solvent, cooling profile, concentration, mixing 
Solvent evaporation Solvent, initial concentration, evaporation rate, 
temperature, pressure, ambient relative humidity 
Precipitation Solvent, anti-solvent, rate of anti-solvent addition, 
mixing, temperature 
Vapor diffusion Solvents, temperature, concentration 
Suspension equilibration Solvent, temperature, solubility, temperature 
programs, mixing, equilibration time 
Crystallization from the melt  Temperature changes (min, max, gradients) 
Quench cooling the melt (A) Cooling rate 
Heat induced transformations Temperature changes 
Sublimation  Temperature gradient, pressure, surface type 
Desolvation of solvates (A) Temperature, pressure 
pH change (A) Temperature, rate of change, acid / conjugate base ratio 
Mechanical treatment (A) 
(i.e. milling, cryo-grinding)  
Milling time, mill type 
Freeze-drying (A) Solvent, concentration, temperature programs 
Spray drying (A) Solvent, concentration, drying temperature 
2.3.2 Solid phase transformations during processing 
In this chapter, examples of pharmaceutical PITs are reviewed. Process steps that 
follow the preparation step of the initial solid form are discussed, but preparative 
process steps such as crystallization, freeze drying and spray drying are not. 
Dissolution testing is also included in this chapter even though it is not a 
manufacturing process. However, all solid dosage forms that are administered orally 
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are subject to aqueous environment of the gastrointestinal tract in which solid phase 
transformations can occur, as well as during in vitro dissolution testing. In addition 
to processing, APIs may undergo solid phase transformations during storage and 
shelf-life, depending on the storage conditions. 
During various process steps materials are subject to mechanical stress, 
temperature changes and different humidities. The different PITs that can occur in 
the solid state are polymorphic transformation, dehydration/desolvation, 
hydrate/solvate formation, and alteration of the crystallinity (crystallization of 
amorphous form and vice versa) (table 3). Multiple solid phase transformations 
during one process step, such as wet granulation, are also possible. Solid phase 
transformations can be solid-solid transformations or solvent-mediated 
transformations. Solid-solid transformations can occur towards higher or lower 
energy forms, but solvent-mediated transformations can only proceed towards lower 
energy and the stable form. The solvent-mediated transformation requires 
dissolution of the metastable phase, and, after the solution has become 
supersaturated with respect to the stable phase (having lower solubility), nucleation 
and growth of the stable phase (Cardew and Davey, 1985). The kinetics of such 
transformations is determined by the dissolution rate of the metastable phase and 
the growth rate of the stable phase (Davey et a ., 1986). l
Table 3. Types of processing-induced solid phase transformations. 
Transformations of solvates other than hydrates are not mentioned 
(Morris et al., 2001; Zhang et al., 2004; Govindarajan and 
Suryanarayanan, 2006). 
Phase transformation Mechanism 
Transformations in the crystalline state 
(polymorphic transformation, 
hydrate formation, dehydration) 
Solid-solid transformation 
Solvent-mediated transformation 
Transformation via melt 
Decrease in the long range order 
(amorphization) 
Solid-solid transformation (i.e. mechanical 
processing induced disorder) 
Transformation via melt 
Increase in the long range order 
(crystallization of amorphous form) 
Solid-solid transformation (i.e. heat or plasticizer 
induced crystallization) 
Solvent-mediated crystallization 
 
Polymorphic transformations have been reported to occur during compression (Chan 
and Doelker, 1985; Otsuka et al., 1989; Matsumoto et al., 1991), milling (Otsuka and 
Kaneniwa, 1986; Shakhtshneider and Boldyrev, 1993; Bauer-Brandl, 1996), wet 
granulation (Davis et al., 2003; Otsuka et al., 2004), the drying phase of wet 
granulation (Davis et al., 2004) and dissolution testing (Lagas and Lerk, 1981). 
Hydrate formation during wet granulation has been reported (Herman et al., 1988; 
Wong and Mitchell, 1992; Otsuka et al., 1999a; Räsänen et al., 2001; Jørgensen et al., 
2002; Airaksinen et al., 2003; Jørgensen et al., 2004; Airaksinen et al., 2005; Sandler 
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et al., 2005; Wikström et al., 2005), as well as during dissolution (Shefter and 
Higuchi, 1963; Kahela et al., 1983; De Smidt et al., 1986; Leung et al., 1998). 
Dehydration during different drying processes has been observed (Räsänen et al., 
2003; Airaksinen et al., 2004; Hausman et al., 2005), and also dehydration induced by 
mechanical treatment (milling and compression) (Ketolainen et al., 1995). Milling 
and grinding have been shown to induce formation of amorphous material (Ward 
and Schultz, 1995; Ticehurst et al., 2000; Mackin et al., 2002; Brodka-Pfeiffer et al., 
2003; Steckel et al., 2003; Ohta and Buckton, 2004; Chikhalia et al., 2006). Humidity 
and temperature affect the solid state of the end product of milling: milling of 
carbamazepine induces formation of amorphous regions, but in humid conditions 
the end product is predominantly the dihydrate (Otsuka et al., 1999b). Low 
temperatures promote low molecular mobility and hence stabilize amorphous solids 
(Andronis and Zografi, 1998). Crystallization of the amorphous form during 
dissolution testing has been observed (Stagner and Guillory, 1979). The 
transformation from the amorphous form to the crystalline form can occur very 
rapidly after administration and therefore the solubility advantage of amorphous 
solids may not always be realized (Hancock and Parks, 2000). The various cases listed 
above show that the occurrence of PITs is by no means rare, and therefore, should 
be continuously monitored. 
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3. Aims of the study 
The aim of this thesis was to apply spectroscopic techniques to solid phase analysis 
within different stages of drug development and manufacturing, and thus, provide a 
molecular level insight into the behavior of APIs during processing. The specific aims 
of the publications included in the thesis were: 
 
? to use near-infrared (NIR) spectroscopy and multivariate methods as tools in 
screening of polymorphs and processing-induced transformations 
 
? to use complementary methods, NIR and Raman spectroscopy, in tandem 
instead of using them in parallel during polymorph screening  
 
? to quantitatively analyze solid phase transformations during fluidized bed 
drying with in-line NIR and Raman spectroscopy 
 
? to investigate dehydration mechanisms with NIR and Raman spectroscopy in 
situ 
 
? to simultaneously measure the drug concentration in the dissolution medium 
and quantitate solid phase transformations in situ with Raman spectroscopy 
during dissolution testing, and use the direct solid phase analysis to explain 
the changes in the dissolution rate 
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4. Experimental 
Experimental details are reported in the original publications (I-V). Polymorphs of 
sulfathiazole are referred to using their corresponding CSD refcodes to avoid 
confusion due to complicated nomenclature in the literature. 
4.1 Materials 
4.1.1 Raw materials 
The model compounds used in the studies were sulfathiazole (STZ) (Orion Pharma, 
Espoo, Finland) (I), theophylline (TP) (BASF, Ludwigshafen, Germany) (III, V), 
nitrofurantoin (NF) (Sigma-Aldrich, Seelze, Germany) (II, V), carbamazepine (CBZ) 
and piroxicam (PRX) (Hawkins, Minneapolis, MN, USA) (IV). The solvents used were 
purified water (I-V), acetone (Sigma-Aldrich, Seelze, Germany) (I, II), 1-propanol 
(Sigma-Aldrich, Seelze, Germany) (I), ethanol (99.5%; Altia, Rajamäki, Finland) (I), 
and 2-propanol (Rathburn Chemicals, Peebleshire, UK) (I). Microcrystalline cellulose 
(MCC) (Penwest Pharmaceuticals, Nastola, Finland) was used as a tablet excipient (V). 
4.1.2 Preparation of solid forms used in the studies 
In the polymorph screening studies STZ and NF were used as received. PRX 
monohydrate, CBZ dihydrate, TP monohydrate, and NF monohydrate were 
crystallized from aqueous solutions. TP anhydrate, NF anhydrate (form β), PRX 
anhydrate (form I), and CBZ anhydrate (form III) were obtained by dehydration of 
their respective monohydrate forms at 100 ºC (TP, PRX, and CBZ) or 130 ºC (NF) under 
reduced pressure (72 mbar), for 24 hours. The high temperature form of CBZ (form I) 
was obtained by heating the raw material at 170 ºC for 2 h. Amorphous CBZ was 
prepared by quench cooling of the melt in liquid nitrogen. 
4.1.3 Preparation of granules for fluidized bed drying studies (III) 
During wet granulation, TP anhydrate undergoes a solvent-mediated solid-state 
transformation into TP monohydrate (Herman et al., 1988). To obtain monohydrate 
granules, raw material was granulated by adding 100 g of purified water to 300 g of 
the dry TP powder at a constant rate (20 g/min) in a planetary mixer (Kenwood 
KM400, Kenwood Ltd., UK). After the addition of water, the wet mass was mixed for 
five minutes. The resulting granules were dried in ambient conditions for 24 h, and a 
sieved fraction between 1 and 2 mm was used in the fluidized bed drying.  
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4.1.4 Preparation of powder compacts for dissolution studies (V) 
Powder compacts for dissolution tests were compressed with a single punch tablet 
machine (Korsch EK0, Erweka Apparatebau, Germany) using flat-faced punches 
(punch diameter = 9 mm). The compacts (m = 150 mg) were compressed to a 
crushing strength of 70 N. The compositions of the powder compacts were 
composed of: 100% TP anhydrate, 100% TP monohydrate, 1:1 (w/w) mixture of TP 
anhydrate and MCC, or 100% NF anhydrate. 
4.2 Methods of analysis 
4.2.1 Near-infrared (NIR) spectroscopy (I-IV) 
Two different NIR spectrometers were used in the studies. In paper I an FT-NIR 
spectrometer (MB-160 DX, Bomem, Quebec, Canada) was used, whereas in papers II-
IV NIR spectrometry was performed with a process-type NIR spectrometer (Control 
Development, South Bend, IN, USA) with a fiber optic probe. NIR spectra were 
recorded of samples in glass vials through the bottom of the vial (diameter of the 
sampling area = 5 mm) (I), crystals on a rotating sample holder (II), granules in a 
fluidized bed dryer through a sight window during drying process (III), and crystals 
on a hot stage during dehydration (IV). 
4.2.2 Raman spectroscopy (II-V) 
A process-type Raman spectrometer (Control Development Inc., South Bend, IN, USA) 
equipped with a fiber optic probe (RamanProbe, InPhotonics, Norwood, MA, USA) 
and a 500 mW laser source (Starbright 785S, Torsana Laser Technologies, Skodsborg, 
Denmark) working at a wavelength of 785 nm was used. Raman spectra were 
recorded of crystals on a rotating sample holder (II), granules in a fluidized bed dryer 
through a sight window during drying process (III), crystals on a hot stage during 
dehydration (IV), and powder compacts in dissolution vessel through a sight window 
during dissolution testing (V). 
4.2.3 Terahertz pulsed spectroscopy (TPS) (II) 
In paper II, terahertz pulsed spectra were recorded using a TPSspectra1000 V 
spectrometer (TeraView, Cambridge, UK). NF samples were mixed with polyethylene 
(Induchem, Volketwil, Switzerland, particle size < 10 µm) and pressed into discs. 
Spectra were recorded at room temperature while the sample chamber was purged 
with dry nitrogen. 
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4.2.4 X-ray powder diffraction and crystal structure verification (I-V) 
XRPD patterns were measured with a theta-theta X-ray powder diffractometer (D8 
Advance, Bruker AXS GmbH, Karlsruhe, Germany). Measurements were performed in 
symmetrical reflection mode with CuKα radiation (λ=1.54 Å) using Göbel mirror bent 
multilayer optics. Crystal structures and all phase transformations were verified by 
comparing the experimental XRPD patterns to the reported structures of the crystal 
forms (I-V). Variable temperature X-ray powder diffraction (VT-XRPD) was used to 
study the structures at different temperatures (I, III, IV). 
The CSD refcodes used for STZ polymorphs were SUTHAZ01 and SUTHAZ02 
(Kruger and Gafner, 1972), SUTHAZ (Kruger and Gafner, 1971), SUTHAZ04 (Babilev 
et al., 1987), and SUTHAZ05 (Hughes et al., 1999). For NF the anhydrate forms α and 
β with the corresponding CSD refcodes LABJON01 and LABJON02 respectively 
(Pienaar et al., 1993a), and monohydrate forms I and II with the CSD refcodes 
HAXBUD01 and HAXBUD respectively (Pienaar et al., 1993b), were used. For PRX, the 
crystal forms were PRX anhydrate (form I) and PRX monohydrate, with CSD refcodes 
BIYSEH (Kojic-Prodic and Ruzic-Toros, 1982), and CIDYAP01 (Reck et al., 1988), 
respectively. The crystal forms and corresponding CSD refcodes of CBZ were 
anhydrate form I, CBMZPN11 (Grzesiak et al., 2003) and anhydrate form III, 
CBMZPN01 (Reboul et al., 1981). The dihydrate form of CBZ was compared to a 
recently reported crystal structure (Harris et al., 2005). Amorphous CBZ was verified 
by the characteristic halo in the XRPD pattern. For TP anhydrate and TP 
monohydrate the CSD refcodes were BAPLOT01 (Ebisuzaki et al., 1997) and 
THEOPH01 (Sun et al., 2002), respectively. 
4.2.5 Thermal analysis (I, III, IV) 
Differential scanning calorimetry (DSC) was performed with a TA Instruments 910S 
differential scanning calorimeter (TA Instruments, New Castle, DE, USA) (I, III, IV). 
Two different apparatuses were used for thermogravimetry (TG): a TGA7 by Perkin 
Elmer (Norwalk, CT, USA) (I) and a TGA 850 by Mettler Toledo (Greifensee, 
Switzerland) (IV). 
4.2.6 Water content analysis (III, IV) 
The water content before and after dehydration on hot stage and fluidized bed 
drying was determined using a Karl Fischer titrator (DL 35, Mettler Toledo, 
Greifensee, Switzerland). 
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4.2.7 Scanning electron microscopy (V) 
The solid-state transformations on the surfaces of the powder compacts were 
investigated by scanning electron microscopy (SEM): powder compacts of TP 
anhydrate and NF anhydrate were immersed in the dissolution medium on Petri 
dishes. Thereafter, the compacts were withdrawn from the dishes at various time 
points and excess dissolution medium was immediately removed from the surface of 
the compact with a tissue. SEM micrographs were recorded with a JSM-840A 
scanning electron microscope (Jeol, Tokyo, Japan). 
4.3 Polymorph screening, processing, and dissolution 
testing 
4.3.1 Polymorph screening (I, II) 
The polymorph screening crystallizations were performed using a 24-well 
crystallization station (H+P Labortechnik, Oberschleissheim, Germany) with a Huber 
cc 250 cryostat (Peter Huber Kältemaschinenbau, Offenburg, Germany). STZ (I) was 
crystallized from 100 ml of 1-propanol, 2-propanol, acetone, ethanol and purified 
water, with a cooling rate of 35 ºC/h. Additional crystallizations for processing 
studies were performed from 2 L of 1-propanol and purified water (to prepare 
polymorphs SUTHAZ01 and SUTHAZ02, respectively). The crystals were harvested by 
filtration, and excess solvent was evaporated from the crystals at 35 ºC and 35% RH, 
for 24 h. Thereafter, the crystals were analyzed with NIR spectroscopy, XRPD, DSC, 
and TG. NF (II) was crystallized from 50 ml of acetone-water mixtures. The water 
contents of the mixtures were 2%, 4%, 10%, 17%, 20%, 25%, 33%, 50%, 67%, and 
75% (v/v). Solutions were heated to 55 ºC (at which all nitrofurantoin had dissolved) 
and cooled to 10 ºC at two different cooling rates (1 ºC/min and 0.0375 ºC/min), with 
and without stirring. In addition to the automated crystallizations, crystallization 
from pure acetone was performed as previously reported (Pienaar et al., 1993a). 
Filtered crystals were dried overnight in ambient conditions and analyzed thereafter 
with NIR spectroscopy, Raman spectroscopy, TPS and XRPD. 
4.3.2 Milling and compression (I) 
STZ crystals were milled and compressed. Milling was performed using a planetary 
ball mill (Pulverisette 6, Fritsch, Idar-Oberstein, Germany). An 80 ml steel bowl was 
used with two different rotation speeds (100 and 400 rpm) and six different milling 
times (1, 2, 5, 10, 20 and 40 min). Compression of the crystals was performed with a 
hydraulic press using three different compression pressures (55, 90 and 180 MPa). 
The milled and compressed samples were analyzed with NIR spectroscopy and XRPD. 
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4.3.3 Fluidized bed drying (III) 
TP monohydrate granules were dried in a multichamber microscale fluidized bed 
dryer (MMFD, Ariacon Oy, Turku, Finland) (Räsänen et al., 2003). A fluidization 
chamber made of glass was modified with a quartz sight window for spectroscopic 
analysis. Two different inlet air temperatures (328 and 333 K) were used in the 
experiments. The batch size (4.5 g) and the flow rate of the inlet air (2.15×10-4 m3 s-1) 
were kept constant throughout the experiments. Prior to the experiments, the 
chamber was heated to 313 K. Process data and in-line NIR and Raman spectra were 
recorded. 
4.3.4 Hot stage dehydration (IV) 
PRX monohydrate and CBZ dihydrate were dehydrated isothermally on a hot stage 
(Mettler Toledo, Greifensee, Switzerland) at different temperatures. The 
temperatures were 381 K, 389 K, 397 K, and 405 K for PRX, and 313 K, 318 K, 323 K, 
328 K, 333 K and 338 K for CBZ. In-situ NIR and Raman spectroscopy were performed 
during dehydration. 
4.3.5 Dissolution testing (V) 
The dissolution tests were conducted with a channel flow intrinsic dissolution test 
apparatus in which only one surface of the powder compact is in contact with the 
dissolution medium (Peltonen et al., 2003). The apparatus was modified with a 
quartz sight window for the Raman probe. The dissolution medium used in the study 
was purified water (t = 25 ºC, V = 500 ml), and the flow rates of the dissolution 
medium were 9 ml/min and 20 ml/min for TP and NF, respectively. The flow rate in 
NF dissolution tests was increased to ensure sink conditions. The concentration of 
the dissolution medium was measured with a UV-Vis spectrophotometer (Ultrospec 
III, Pharmacia LKB Biotechnology, Sweden) and a flow-through cuvette. The solid 
state of the dissolving compact was measured in situ with Raman spectroscopy. 
4.4 Data processing 
4.4.1 Spectral treatment 
Different treatment methods were used to improve the signal/noise ratio, remove 
the baseline and scale differences between the spectra. The methods applied were 
Savitzky-Golay 2nd derivative treatment (Savitzky and Golay, 1964) (I), standard 
normal variate (SNV) transformation (Barnes et al., 1989) (I-V), and multiplicative 
scatter correction (MSC) (Geladi et al., 1985) (I, IV). In paper II, NIR and Raman 
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spectra were first treated with SNV transformation, and then merged into one array 
prior to further processing. 
4.4.2 Qualitative and quantitative methods 
The following multivariate methods were used to qualitatively or quantitatively 
analyze the spectral data: principal component analysis (PCA) (I, II), dendrogram 
cluster analysis (I), partial least squares discriminant analysis (PLS-DA) (IV), and partial 
least squares regression (PLS) (III). In paper V the solid phase was quantified by 
ratioing peak intensities in the Raman spectra characteristic of each solid form 
involved. Quantification models were composed and spectra were pre-processed and 
analyzed using MatLab (Mathworks, Natick, MA, USA) and Simca-P software 
(Umetrics AB, Umeå, Sweden). 
In paper III, PLS quantification was based on calibration NIR and Raman 
spectra recorded of binary powder mixtures with known ratios of anhydrous TP and 
TP monohydrate. The number of binary mixture samples used in the calibration sets 
was 59 and 22 for NIR and Raman, respectively. The quantification models were 
tested using independent test sets of 10 binary mixture samples of known ratios. 
In paper IV, PLS-DA models were constructed using NIR and Raman spectra of 
pure solid forms of PRX (form I and monohydrate) and CBZ (form I, form III, 
dihydrate and amorphous form). The PLS-DA model of PRX was constructed using 12 
samples of each form, and tested using 3 independent samples of each form. CBZ 
models were constructed using 8 samples of each form, and tested with 1 sample of 
each form.  
In paper V, quantification of the solid forms was based on calibration curves 
constructed using Raman spectra of anhydrate and monohydrate powder mixtures 
of TP and NF. Two peaks characteristic of the corresponding anhydrate form, and 
one of the corresponding monohydrate were used. A ratio of peak intensities was 
calculated for each calibration sample (the monohydrate peak intensity divided by 
the sum of all three characteristic peak intensities) and thereafter, the calculated 
ratios were correlated to the hydrate form contents of the samples. Twenty-two 
samples were used to build the calibration curve and 11 independent samples were 
used as a test set.  
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5. Results and discussion 
5.1 Solid phase analysis using spectroscopy 
Figure 5 shows NIR spectra, terahertz pulsed spectra and Raman spectra of three 
solid forms of nitrofurantoin (NF) (II). The different characteristics of the three 
methods are visible in the spectra. 
Spectral information in the NIR region is composed of combinations and 
overtones of the fundamental vibrations associated with C-H, O-H, and N-H bonds. 
Hence, NIR spectroscopy is sensitive to differences in hydrogen bonding between the 
molecules in the crystal lattice (intermolecular bonding). Also, the presence of water 
molecules and hydrogen bonding interactions between the API and water molecules 
strongly influences the NIR spectra of solid drugs. These features can be seen in the 
NIR spectra of NF (figure 5a). The NIR spectrum of NF monohydrate form II is 
dominated by features due to the presence of water. The NIR spectra of all three 
forms contain bands in the region 1600-1750 nm indicating similarities in the 
intramolecular bonding. Regardless of the common bands mentioned, the anhydrate 
forms α and β have differences in the intermolecular bonding. These are indicated by 
bands in the 1st overtone and combination band region in the NIR spectrum of form 
β. NIR spectroscopy has been used for a wide variety of pharmaceutical analyses 
(Ciurczak and Drennen, 2002) including determination of crystallinity (Blanco et al., 
2000; Seyer et al., 2000; Seyer and Luner, 2001), polymorphic forms (Gimet and 
Luong, 1987; Dreassi et a ., 1995; Norris et al., 1997; Luner et al., 2000; Patel et al., 
2001), and hydrates (Räsänen et al., 2001; Airaksinen et al., 2003; Airaksinen et al., 
2005). 
l
l
TPS is most sensitive to intermolecular bonding since it mainly probes 
intermolecular vibrations including crystalline phonon vibrations. The three NF forms 
exhibited uniform and easily separable terahertz pulsed spectra (figure 5b). At 
present these modes cannot be assigned to specific phonon vibrations, but despite 
the present difficulties in interpreting terahertz spectra, the differences between the 
spectra of the NF forms show that TPS is another potential spectroscopic tool for 
polymorph screening. Like NIR and Raman spectroscopy, TPS has been used for 
analysis of polymorphism (Taday et al., 2003; Zeitler et al., 2006b) and crystallinity 
(Strachan et a ., 2004b; Strachan et al., 2005), as well as hydrates (Liu et al., 2006; 
Zeitler et al., 2006a). 
Raman spectroscopy predominantly detects symmetric vibrations of nonpolar 
(mainly C-C) and aromatic groups. These vibrations can be affected by intramolecular 
events like molecular conformation and bonding changes. Each NF form exhibited 
distinct Raman spectra (figure 5c). Raman spectroscopy has been used to analyze 
crystallinity (Taylor and Zografi, 1998; Schmidt et al., 2003; Okumura and Otsuka, 
2005), polymorphic forms (Tudor et al., 1993; Langkilde et al., 1997; Taylor and 
Langkilde, 2000; Strachan et al., 2004a), and hydrates (Rantanen et al., 2005; 
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Wikström et a ., 2005). Unlike NIR spectroscopy, Raman spectroscopy can be used in 
aqueous media, since water is a poor Raman scatterer. 
l
 
Figure 5. Spectroscop c characterization of three NF forms (monohydrate II, and 
anhydrates α and β). (a) NIR spectra, (b) terahertz pulsed spectra, and (c) 
Raman spectra. Modified from paper II. 
i
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5.2 Spectroscopic methods as polymorph screening tools 
Sulfathiazole (STZ) crystallizations yielded three polymorphs (SUTHAZ01, SUTHAZ02, 
and SUTHAZ), which were verified by XRPD and DSC (I). It was confirmed by TG that 
no solvates had been formed. The XRPD patterns of STZ polymorphs resemble each 
other and therefore, identification with XRPD alone would not have been reliable. 
As a further complication, the samples were mixtures of different polymorphs. It has 
been reported that STZ crystallizes according to the Ostwald’s rule of stages 
(Ostwald, 1896), and accordingly, initially crystallizes in the least stable form, and 
stepwise, converts towards the stable form (Blagden et al., 1998a; Blagden et al., 
1998b). Based on this rule, the time point of crystal harvesting partially determines 
the final crystal form. The main polymorph from water was SUTHAZ02, and a 
mixture of SUTHAZ and SUTHAZ02 was obtained from ethanol. From 1-propanol the 
polymorphic content was mainly SUTHAZ01, and crystallization from 2-propanol 
yielded a mixture of the three forms mentioned. Similar results have been published 
previously (Khoskhoo and Anwar, 1993; Blagden et al., 1998a; Blagden et al., 1998b). 
NIR spectroscopy helped to differentiate between the crystallized samples. 
Second derivative treatment was more efficient than SNV transformation or MSC. 
The difference between NIR spectra of SUTHAZ and SUTHAZ02 is very small, and this 
difference was most obvious after second derivative treatment. Spectral differences 
between SUTHAZ01 and the other forms were obvious due to distinctly different 
hydrogen bonding between the STZ molecules. Initially, the distances between the 
second derivative NIR spectra were visualized using dendrogram cluster analysis. This 
method was able to cluster the samples that contained mainly SUTHAZ01 in one 
group but the other forms were clustered together in another group, so only a 
partial clustering was achieved. The second method applied, PCA, was able to 
differentiate between all three polymorphs. The scores of the PCA were plotted, and 
two principal components were not enough to separate polymorphs SUTHAZ and 
SUTHAZ02 into their own clusters. The third principal component explained only 
0.6% of the spectral variation, but was essential, since it separated the scores of 
forms SUTHAZ and SUTHAZ02 (figure 6).  
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Figure 6. PCA score p ot of the second derivative NIR spectra of the crystallized
samples. The legend refers to the crystallization solvents. The principal 
components PC1, PC2, and PC3 together explained 99.4% of the NIR 
spectral variation. Polymorphic purity increases in the direction of the 
arrows. Modified from paper I. 
l  
Two anhydrate forms (α and β) and the monohydrate form II were crystallized in the 
polymorph screen of NF (II). The three forms were identified with three 
complementary spectroscopic techniques (NIR, Raman and TPS, figure 5) and verified 
with XRPD. As expected, the water content of the solvent most affected the 
outcome of the crystallization. With water contents above 4%, the resulting crystal 
form was always form II, regardless of the cooling rate or whether stirring was used. 
Interestingly, at low water contents (2% and 4%), hydrate formation could be 
controlled by the stirring and cooling rate. At a water content of 2%, the unstirred 
crystallizations yielded form II crystals, but stirring led to form α or β. With a water 
content of 4%, a combination of slow cooling and stirring produced crystals of form 
α, whereas crystallizations with fast cooling and stirring resulted in form II. These 
results underline the need to consider not only the solvent, but also various 
processing parameter effects.  
The rationale behind the combination of NIR and Raman spectroscopy is that 
they are fast methods that require no or very little sample preparation and are 
suitable for high throughput polymorph screening. Furthermore, they are 
complementary. Instead of comparing the results obtained with various techniques, 
coupling complementary techniques may be useful. In the PCA of the merged 
spectra, two principal components were needed to separate the scores of the three 
solid forms (figure 7a). The first principal component separated the monohydrate 
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from the anhydrate forms, while the second principal component separated the two 
anhydrate forms from each other. The first principal component had the largest 
loading values in the NIR spectral region (at 1416 nm and 1920 nm), which 
corresponds to the presence of water molecules in form II (figure 7b). The most 
important loadings of PC2 were in the Raman spectral region (between 1343 cm-1 
and 1349 cm-1). Thus, NIR spectroscopy effectively separated the hydrate form from 
the anhydrates, and Raman spectroscopy differentiated the anhydrate forms α and β.  
 
Figure 7. a) PCA score plot of the SNV corrected and merged NIR/Raman spectra. 
The three clusters rep esent crystal forms II, α and β of nitrofurantoin. The 
principal components PC1 and PC2 together explained 94.2% of the 
NIR/Raman spectral variation. b) The loadings of the principal 
components PC1 and PC2. Modified from paper II. 
r
5.3 Spectroscopic analysis of processing-induced 
transformations 
5.3.1 The effect of milling and compression 
Since the conditions APIs are likely to meet during pharmaceutical production set 
the stage for PITs, analysis of the solid phase should be carried out also during 
processing. In paper I, PIT screening of STZ was performed. During milling, a 
decrease in crystallinity of STZ was observed as peak broadening in the XRPD 
patterns. Crystallinity decreased as a function of milling speed and time due to the 
higher energy input. Preferred orientation of the samples with slower milling speed 
made interpretation of XRPD patterns difficult, particularly with crystals of form 
SUTHAZ02. Therefore, complementary methods were needed. NIR analysis showed 
the decrease of crystallinity, but also a transformation from SUTHAZ02 to SUTHAZ01. 
This polymorphic transformation was not visible in the XRPD (due to the preferred 
orientation).  
The NIR spectra of the processed samples were analyzed with PCA, and the 
milling-induced transformations were visualized using a PCA score plot. In the score 
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plot, the polymorphic transformation was mainly seen in the direction of the first 
principal component, and the decrease in crystallinity was seen in the direction of 
the second principal component. Even though the pressures used were rather high, 
no phase transformations were detected after compression of STZ crystals. 
5.3.2 Solid phase analysis during fluidized bed drying 
In paper III, fluidized bed drying of theophylline (TP) monohydrate granules was 
studied. During drying, TP monohydrate dehydrated to TP anhydrate at both 
temperatures investigated. The dehydration could be identified by following either 
the absolute humidity of outlet air or pressure difference over the fluidized bed. 
These measurements indicate the water loss from the crystalline lattice and the 
weight loss due to dehydration, respectively. However, no molecular level insight 
into the system is achieved and possible underlying structural changes cannot be 
identified with these data. 
The dehydration was directly analyzed with in-line NIR and Raman 
spectroscopy: NIR spectroscopic quantification results showed that the TP 
monohydrate content of the granules started to decrease immediately after the 
fluidization had started (figure 8a). This was also seen as an increase in outlet air 
humidity and a decrease in pressure difference over the bed. Dehydration was 
completed and, according to NIR spectroscopy, reached a plateau after fluidization 
for 7 minutes at 328 K and 6 minutes at 333 K. At these time points humidity of the 
outlet air was highest. A change in the Raman spectroscopic quantification of 
hydrate form was detected after a 3-minute lag time (figure 8b). This change is 
related to differences in molecular packing of TP solid-state forms (figure 9).  
 
Figure 8. Dehydration profiles during fluidized bed drying of theophylline 
monohydra e granules. Quantification of hydrate form by in-line (a) NIR 
spectroscopy and (b) Raman spectroscopy with PLS regression. Modified 
from paper III. 
t
The crystal structure started to change after water molecules had left the water 
channels (figure 9d), thereafter the amount of hydrate form decreased rapidly until 
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no more water could be removed from the structure. Unlike with NIR spectroscopy, 
quantification with Raman spectroscopy did not reach a plateau when the outlet air 
humidity was highest. A clear difference between experiments at different 
temperatures was noticed in the Raman spectroscopic results (figure 8b). The 
amount of hydrate decreased faster at 333 K than at 328 K and reached a lower 
level, after which the amount of hydrate decreased much more slowly. The slight 
downward trend seen after the rapid decrease in the amount of hydrate in the 
Raman spectroscopic quantification is probably related to the existence of the 
metastable anhydrate form (Phadnis and Suryanarayanan, 1997), not to the presence 
of monohydrate form in the granules. The occurrence of the metastable form has 
been linked to dehydration in open conditions in DSC studies (Suihko et al., 1997), 
and the relative amount of the metastable form during drying has been found to be 
dependent on dehydration conditions: fluidized bed drying promotes metastable 
anhydrate formation compared to tray drying. (Airaksinen et al., 2004). Obviously, 
the amount of metastable form could not be quantified since it was not included in 
the PLS calibration model. All intermediate forms that are detected during solid 
phase transformations should be included in the calibration samples. This aspect was 
studied in paper IV.  
 
Figure 9. Molecular structure of theophylline (TP) (a), and arrangement of 
molecules and hydrogen bonding in TP anhydrate (b), TP monohydrate 
(c), and TP monohydrate viewed along a water channel (d). Dotted lines 
represent hydrogen bonds, water molecules are highlighted. Modified 
from paper III. 
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5.3.3 Investigation of dehydration mechanisms 
In paper IV, the dehydration of piroxicam (PRX) monohydrate and carbamazepine 
(CBZ) dihydrate was investigated. PRX and CBZ showed very different dehydration 
behavior. The dehydration of PRX monohydrate was very straightforward, whereas 
the dehydration of CBZ dihydrate was complicated. A heating-induced dehydration 
from PRX monohydrate straight to PRX form I was observed very successfully with 
NIR and Raman spectroscopy. No intermediate solid forms were observed during the 
dehydration. This finding was supported by VT-XRPD analysis of non-isothermal 
dehydration. Since the dehydration involved only two solid forms, one component 
alone explained the whole variation in PLS-DA analysis.  
DSC analysis of CBZ dihydrate showed one broad endotherm, but VT-XRPD 
analysis revealed that the dehydration was not as simple as one might have expected 
from the DSC trace. The removal of the water from the crystal lattice of CBZ 
dihydrate initially resulted in a decrease in crystallinity. This was seen in the XRPD 
pattern as a sudden drop in peak intensities. After additional heating form III peaks 
appeared, which were eventually followed by form I peaks. The PLS-DA of the in-situ 
NIR and Raman spectra recorded during dehydration showed differences due to the 
intrinsic nature of the methods. With both methods, a three-component model was 
used. In NIR spectral PLS-DA, the first component explained 76.3% of the spectral 
variation and separated the dihydrate from anhydrate forms (form I, form III, and 
amorphous). The second component, explaining 17.8%, separated the amorphous 
form, and third component, explaining 5.5%, discriminated between form I and 
form III. Like in the fluidized bed drying paper (III), NIR spectroscopy was a powerful 
method for determining interactions between the API and water. The differences 
between the spectra of the anhydrous forms (form I, form III and amorphous) were 
smaller and the intermediate forms during dehydration could not be as accurately 
followed, although differences in the dehydration paths could be observed. In 
Raman spectral PLS-DA, the first component explained 73.0% and separated 
crystalline forms (dihydrate, form I, and form III) from the amorphous form (figure 
10a and 10b). The second component, explaining 19.9%, separated the dihydrate, 
and third component, explaining 6.3%, discriminated between forms I and III. The 
paths of dehydration were more accurately followed by Raman spectroscopy than 
NIR spectroscopy, since Raman spectroscopy is more sensitive to structural changes. 
Regardless of CBZ being classified as a channel hydrate, removal of water involves 
reorganization of the CBZ molecules in the lattice and can be well observed with 
Raman spectroscopy. At higher temperatures dehydration was fast and proceeded 
via the amorphous form, whereas at lower temperatures dehydration was slower 
and not as destructive and the scores of in-situ Raman spectra were located further 
from the scores of the pure amorphous form (figure 10a). 
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Figure 10. (a) PLS-DA score plot of dehydration of CBZ dihydrate investigated by in-
situ Raman spectroscopy. Squares and triangles represent scores of in-
situ Raman spectra at d fferent temperatures, hexagons are scores of
pure solid forms (calibration samples). (b) Weight vectors of the Raman 
spectroscopic PLS-DA model. Modified from paper IV. 
i  
l
5.4 In-situ solid phase analysis during dissolution testing 
The effect of solid form on the dissolution rate of APIs can be investigated by 
measuring the intrinsic dissolution rate (IDR). However, there are also several 
properties other than the solid form that can affect the dissolution rate, and 
furthermore the dissolution rates of different forms are not always in line with 
corresponding solubilities (Allen et a ., 1978; Kahela et al., 1983; Kristl et al., 1996; 
Laihanen et al., 1996). A change in the IDR is not a reliable measure of a solid phase 
transformation during dissolution test. Therefore, direct solid phase analysis was 
applied to dissolution testing (Rantanen et al., 2006) (figure 11). The combination of 
liquid and solid phase analysis enables understanding of dissolution as a whole. 
 
Figure 11. Dissolution testing cheme. s
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During dissolution TP anhydrate underwent a transformation to TP monohydrate. 
Almost immediately after the compact prepared from 100% TP anhydrate was 
exposed to water, transformation to TP monohydrate started. The dissolution rate of 
the initially anhydrous compact decreased as the amount of monohydrate form 
increased (figure 12). The transformation was seen with SEM as rapid growth of 
needle-like TP monohydrate crystals on the surface of the compact (figure 10a-c). 
During the transformation dissolution of both forms and crystallization of the 
monohydrate form occurred. Consequently, the larger the amount of monohydrate 
the slower the dissolution rate of the compact. Once the solid phase transformation 
was complete, the dissolution rate of the initially anhydrous surface became 
constant (at ~6 min, figure 12c). At this stage the anhydrate form was no longer 
present and therefore only the monohydrate phase dissolved. Even though the 
surface of the compact was fully transformed to monohydrate, the dissolution rate 
remained higher than that of a compact prepared from TP monohydrate. The 
dissolution rate difference between the transformed, initially anhydrous compact 
and the compact prepared from TP monohydrate was most likely caused by a 
difference in the specific surface area due to the monohydrate crystal growth on the 
initially anhydrous surface (figure 12a-c).  
The surface of the compact consisting of a 1:1 mixture of TP anhydrate and 
MCC started to convert to TP monohydrate after a lag time of approximately two 
minutes. The presence of MCC delayed the transformation onset but had no 
significant effect on the transformation rate once the transformation was underway. 
Similar hydrate formation delaying behavior due to MCC has also been detected in 
an aqueous processing environment and vapor phase induced solid phase 
transformation studies (Airaksinen et al., 2003; Salameh and Taylor, 2006). 
Analogously to TP, NF anhydrate (form β) transformed to NF monohydrate 
(form II) during dissolution. The transformation was an order of magnitude slower 
than the transformation of TP anhydrate. This can be explained by the considerable 
difference between the solubilities of TP and NF. Unlike with TP, the correlation 
between the solid phase transformation and IDR changes was not evident with NF. 
There was no clear decrease in the dissolution rate during the transformation stage. 
The dissolution rate of compacts prepared from NF anhydrate started to decrease 
immediately after the dissolution test began and became constant after 
approximately 8 minutes. This result is consistent with dissolution studies performed 
with the rotating disk method (Otsuka et al., 1992). The fast dissolution rate at the 
very beginning can be partly explained by the dissolution of NF anhydrate before 
the monohydrate began to crystallize. Further, the dissolution of loose NF particles 
on the surface can promote the burst effect during the first minutes. The dissolution 
rate then increased after approximately 50 minutes and decreased again after 200 
minutes. The variation of the dissolution rate can be due to several overlapping 
factors, e.g., the changing anhydrate/monohydrate ratio and the decreasing rate of 
hydrate formation. Also, the increase in the specific surface area may partly 
compensate for the lower dissolution rate of the monohydrate form.  
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Figure 12. Results of the dissolution test of TP anhydrate. a), b), and c) are time
points at which the surface of the compact was investigated with (off-
line) SEM. For comparison, dissolution rate of TP monohydrate is shown 
(dashed line). Modified from paper V. 
 
5.5 Interfacing spectroscopic tools with different 
environments 
With fiber optic probes spectrometers can be interfaced with a variety of 
environments, but there are several pitfalls that have to be avoided. Measurements 
can be performed non-invasively or in situ using immersion probes or through a 
spectroscopic window. Possible pitfalls include poor sampling and sticking of 
material to the probe/window. Sampling errors can be avoided by increasing the 
effective sample volume and by moving the sample or the probe during 
measurements (Bell et al., 2004). In this thesis, a large sampling area (I) and a 
rotating sample holder (II) were used to ensure representative sampling. In process 
measurements the samples are rarely static, so sampling area is usually not an issue. 
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In the fluidized bed drying study (III), it was visually confirmed that the granules 
were well fluidized and the window remained clean during the experiments. If 
spectra are measured through a window, the material of the window is of 
importance. In this thesis, quartz windows were used to avoid unwanted spectral 
features (III, V). 
When quantitative analysis is performed, development and choice of the 
suitable quantitative method is important. One can use either univariate or 
multivariate methods. Univariate methods are straightforward and easier to apply 
than multivariate methods. If good quality spectra are obtained and peaks 
characteristic of each form to be quantified can be identified, simple univariate 
quantification is advisable. In paper V, where static samples were under 
investigation, ratioing intensities of three Raman peaks enabled reliable 
quantification, and thus, complicated methods were not needed. Multivariate 
methods can extract information from regions of or entire spectra and are 
particularly useful for coping with cross-correlated and noisy data (Beebe et al., 
1988). In paper III, PLS regression was used to obtain quantitative information from 
in-line spectra that contained considerable amounts of process-related noise. 
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 6. Conclusions 
Near-infrared (NIR) spectroscopy can be utilized in screening of polymorphs and 
processing-induced transformations (PITs). With principal component analysis (PCA) 
it is possible to analyze large amounts of samples and differentiate between spectra 
that contain very slight differeces. By using NIR and Raman spectroscopy in tandem a 
clear classification of solid forms during polymorph screening was achieved. The 
complementary nature of the methods is best realized when analyzing complicated 
systems that exist as several solid forms. 
Quantitative solid phase analysis can be performed during fluidized bed 
drying using in-line NIR and Raman spectroscopy and partial least squares (PLS) 
regression. To quantitate all solid forms upon dehydration, the dehydration 
mechanism has to be investigated first. This can be carried out with in situ 
spectroscopy and partial least squares discriminant analysis (PLS-DA).  
-
Simultaneous analysis of the liquid and the solid phase in situ during 
dissolution testing enables analysis of dissolution as a whole. Direct solid phase 
analysis of the dissolving solid sample provides a science-based explanation for 
changes in the dissolution rate. 
Spectroscopic methods are well suitable for solid phase analysis during 
pharmaceutical development and manufacturing, and provide means for analyses 
throughout the life cycle of the drug product. In-line measurements can be 
performed, providing molecular level information on API behavior during 
processing. This enables better understanding and knowledge of the drug products 
and processes, and therefore, a way to achieve better quality. 
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